| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
|
N Engl J Med
|
2009
|
10.21
|
|
2
|
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
|
J Hepatol
|
2013
|
5.64
|
|
3
|
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
|
N Engl J Med
|
2014
|
3.40
|
|
4
|
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
|
N Engl J Med
|
2015
|
3.13
|
|
5
|
IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections.
|
Hepatology
|
2015
|
2.76
|
|
6
|
Faldaprevir and deleobuvir for HCV genotype 1 infection.
|
N Engl J Med
|
2013
|
2.68
|
|
7
|
[Clinical practice guidelines on the use of liver biopsy].
|
Gastroenterol Clin Biol
|
2002
|
2.22
|
|
8
|
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.
|
Hepatology
|
2011
|
2.11
|
|
9
|
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
|
Gastroenterology
|
2006
|
2.07
|
|
10
|
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages.
|
Clin Chem
|
2007
|
1.84
|
|
11
|
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
|
J Hepatol
|
2010
|
1.63
|
|
12
|
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.
|
Liver Int
|
2008
|
1.62
|
|
13
|
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
|
J Hepatol
|
2011
|
1.60
|
|
14
|
[Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy].
|
Presse Med
|
2007
|
1.38
|
|
15
|
Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection.
|
J Clin Microbiol
|
2006
|
1.36
|
|
16
|
Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus.
|
Comp Hepatol
|
2005
|
1.25
|
|
17
|
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
|
J Hepatol
|
2006
|
1.18
|
|
18
|
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
|
Clin Gastroenterol Hepatol
|
2012
|
1.16
|
|
19
|
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection.
|
Hepatology
|
2006
|
1.15
|
|
20
|
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
|
Hepatology
|
2013
|
1.14
|
|
21
|
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
|
Gastroenterology
|
2012
|
1.09
|
|
22
|
Dried blood spot sampling for hepatitis B virus serology and molecular testing.
|
PLoS One
|
2013
|
1.04
|
|
23
|
Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data.
|
Clin Biochem
|
2008
|
1.01
|
|
24
|
Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
|
J Med Virol
|
2006
|
0.97
|
|
25
|
Possible zoonotic transmission of hepatitis E from pet pig to its owner.
|
Emerg Infect Dis
|
2007
|
0.97
|
|
26
|
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy.
|
PLoS One
|
2012
|
0.92
|
|
27
|
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.
|
Antimicrob Agents Chemother
|
2013
|
0.91
|
|
28
|
Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots.
|
PLoS One
|
2012
|
0.89
|
|
29
|
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.
|
Eur J Gastroenterol Hepatol
|
2009
|
0.89
|
|
30
|
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.
|
Liver Int
|
2012
|
0.88
|
|
31
|
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.
|
Dig Liver Dis
|
2011
|
0.86
|
|
32
|
Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay.
|
J Clin Microbiol
|
2008
|
0.86
|
|
33
|
Hepatitis B virus genotypes and extrahepatic manifestations.
|
J Hepatol
|
2005
|
0.84
|
|
34
|
Medically assisted procreation and transmission of hepatitis C virus: absence of HCV RNA in purified sperm fraction in HIV co-infected patients.
|
AIDS
|
2006
|
0.83
|
|
35
|
[Hepatitis B virus genotypes: clinical, epidemiological and therapeutic implications].
|
Gastroenterol Clin Biol
|
2002
|
0.82
|
|
36
|
Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy.
|
AIDS
|
2008
|
0.82
|
|
37
|
Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection.
|
Gut
|
2010
|
0.82
|
|
38
|
Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
|
Eur J Gastroenterol Hepatol
|
2016
|
0.81
|
|
39
|
Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
|
J Med Virol
|
2010
|
0.81
|
|
40
|
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.
|
Antivir Ther
|
2013
|
0.81
|
|
41
|
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
|
J Hepatol
|
2002
|
0.80
|
|
42
|
Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study.
|
Gastroenterol Clin Biol
|
2007
|
0.80
|
|
43
|
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4).
|
Antivir Ther
|
2015
|
0.80
|
|
44
|
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: complete biochemical and histological response to therapy with ursodesoxycholic acid.
|
J Gastroenterol Hepatol
|
2006
|
0.78
|
|
45
|
[Sarcoidosis following pegylated interferon therapy: two cases].
|
Gastroenterol Clin Biol
|
2006
|
0.77
|
|
46
|
Peripheral blood cytopenia before treatment in HCV patients: is it a limitation for HCV treatment in the era of DAA?
|
Liver Int
|
2012
|
0.76
|
|
47
|
Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
|
J Gastroenterol Hepatol
|
2013
|
0.76
|
|
48
|
How should chronic hepatitis B virus infection be managed in HIV-hepatitis B virus-coinfected patients not eligible for concomitant antiretroviral therapy?
|
AIDS
|
2008
|
0.75
|
|
49
|
Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
|
Eur J Gastroenterol Hepatol
|
2008
|
0.75
|
|
50
|
Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.
|
Liver Int
|
2013
|
0.75
|
|
51
|
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
|
J Hepatol
|
2002
|
0.75
|
|
52
|
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
|
AIDS
|
2016
|
0.75
|
|
53
|
Optimizing treatment outcomes in chronic hepatitis C: management of non-response.
|
Antivir Ther
|
2006
|
0.75
|
|
54
|
[HCV non-responder patients: definition of non-response and treatment strategy].
|
Gastroenterol Clin Biol
|
2007
|
0.75
|
|
55
|
NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
|
Eur J Gastroenterol Hepatol
|
2017
|
0.75
|